Last reviewed 2026-04-22 · How we verify

BHV-4157

BHV-4157 is a selective serotonin 5-HT1F receptor agonist that reduces neuronal activity and neuropeptide release to treat acute migraine.

BHV-4157 is a selective serotonin 5-HT1F receptor agonist that reduces neuronal activity and neuropeptide release to treat acute migraine. Used for Acute migraine treatment.

At a glance

Mechanism of action

5-HT1F receptor agonists work by binding to serotonin receptors on trigeminal nerve terminals and inhibiting the release of pro-inflammatory neuropeptides like calcitonin gene-related peptide (CGRP). This reduces neuroinflammation and pain signaling in migraine pathways. BHV-4157 is designed as a selective 5-HT1F agonist with potential advantages in migraine acute treatment.

Approved indications

• Acute migraine treatment

Common side effects

• Dizziness
• Somnolence
• Paresthesia
• Nausea

Key clinical trials

• Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder (PHASE3)
• Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder (PHASE2, PHASE3)
• Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control
• Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)
• A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma (EARLY_PHASE1)
• A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (PHASE2, PHASE3)
• Open Pilot Trial of BHV-4157 (PHASE3)
• Randomized Trial of Adult Participants With Generalized Anxiety Disorder (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.